Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

doi:10.1186/1478-7547-7-4

Download references

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Nicolas M Furiak, Haya Ascher-Svanum^*, Robert W Klein, Lee J Smolen, Anthony H Lawson, Robert R Conley and Steven D Culler

* Corresponding author: Haya Ascher-Svanum haya@lilly.com

Cost Effectiveness and Resource Allocation 2009, 7:4 doi:10.1186/1478-7547-7-4

Include	Article citation and all cited references Cited references only Article citation only
Format	EndNote, Zotero or Papers Reference Manager Refworks BibTeX

Cost Effectiveness and Resource Allocation

Viewing options

Associated material

Tools

Download references

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Cost Effectiveness and Resource Allocation

Viewing options

Associated material

Related literature

Cited by

Other articles by authors

Related articles/pages

Tools

Download references

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States